Cite
HARVARD Citation
Pasqualini, C. et al. (2021). Phase II and biomarker study of programmed cell death protein 1 inhibitor nivolumab and metronomic cyclophosphamide in paediatric relapsed/refractory solid tumours: Arm G of AcSé-ESMART, a trial of the European Innovative Therapies for Children With Cancer Consortium. European journal of cancer. pp. 53-62. [Online].